MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms. (Q54444264)

29 May 2018

title

MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms. (English)

1 reference

29 May 2018

9

A Tefferi

1 reference

29 May 2018

M M Patnaik

1

1 reference

29 May 2018

T L Lasho

2

1 reference

29 May 2018

C M Finke

3

1 reference

29 May 2018

N Gangat

4

1 reference

29 May 2018

D Caramazza

5

1 reference

29 May 2018

S Siragusa

6

1 reference

29 May 2018

C A Hanson

7

1 reference

29 May 2018

A Pardanani

8

1 reference

29 May 2018

publication date

28 January 2010

1 reference

29 May 2018

published in

Leukemia

1 reference

29 May 2018

volume

24

1 reference

29 May 2018

issue

4

1 reference

29 May 2018

page(s)

859-860

1 reference

29 May 2018

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.1

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.1

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.1

The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.1

The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.1

JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.1

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.1

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.1

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.1

Mutations of ASXL1 gene in myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.1

Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.1

inferred from DOI database lookup

7 January 2021

based on heuristic

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.1

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2010.1

1 reference

29 May 2018

1 reference

29 May 2018